References
- Pimpinelli N, Olsen EA, Santucci M, et al.; International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053–1063.
- Shin J, Monti S, Aires DJ, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007;110:3015–3027.
- Wong HK, Mishra A, Hake T, et al. Evolving insights on the pathogenesis and therapy of cutaneous T-cell lymphoma. Br J Haematol 2011;155:150–166.
- Garzon R, Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol 2012;24: 655–659.
- Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2012;73:473–477.
- Fabbri M, Croce CM, Calin GA. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 2009;50:160–170.
- Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010;116:1105–1113.
- Husby S, Geisler C, Grønbæk K. MicroRNAs in mantle cell lymphoma. Leuk Lymphoma 2013 Feb 19. [Epub ahead of print]
- Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011;118:5891–5900.
- Kopp KL, Ralfkiaer U, Gjerdrum LMR, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013 May 15. [Epub ahead of print]
- He J, Zhang F, Wu Y, et al. Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis. Dis Markers 2013 Mar 12. [Epub ahead of print]
- Sonkoly E, Janson P, Majuri ML, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 2010;126:581–589.e1–20.